Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Memento-Plus
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
1 other identifier
observational
1,028
1 country
26
Brief Summary
Dementia is a clinical syndrome that is the result of distinct underlying pathologies including Alzheimer's disease (AD). Despite more than two decades of research on prevention and treatment of dementia and aging-related cognitive decline, highly effective preventive and therapeutic strategies remain elusive. Many features of dementia render it especially challenging. Indeed development of disease occurs insidiously over the course of years or decade. In addition, the causes of dementia and determinants of its severity are likely multi-factorial. To overcome these challenges and better understand the causes and course of AD and related disorders, long term follow-up studies of persons at high risk of dementia are required including multidimensional and harmonized assessment of risk factors, phenotypes (cognition, neuropsychiatric symptoms, physical health, self rated health) and endophenotypes (blood markers, genetic markers, neuroimaging markers). This project proposes an extension of the follow-up of Memento participants over 5 to 10 years with of focus on cognitive outcomes and comorbidities.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2019
Longer than P75 for all trials
26 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 27, 2019
CompletedFirst Posted
Study publicly available on registry
October 1, 2019
CompletedStudy Start
First participant enrolled
December 3, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 20, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 20, 2024
CompletedFebruary 17, 2025
February 1, 2025
5.1 years
September 27, 2019
February 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)
Each 12 months from baseline for 5 years
Secondary Outcomes (7)
Mortality
Each 12 months from baseline for 5 years
Loss of autonomy based on functional activity assessment
Each 12 months from baseline for 5 years
Rate of cognitive decline based on change in cognitive performances
Each 12 months from baseline for 5 years
Incidence of neurovascular and cardiovascular events (Stroke and Coronary events)
Each 12 months from baseline for 5 years
Quality of life: EQ-5D (EUROQOL)
Each 12 months from baseline for 5 years
- +2 more secondary outcomes
Study Arms (1)
Individuals at high risk of developing Alzheimer's dementia
Eligibility Criteria
Outpatients from French Research Memory Centers and included in Memento cohort
You may qualify if:
- Participants aged over 18 year-old
- Being included in Memento cohort
- Affiliated person or beneficiary of a social security scheme.
- Participants capable of expressing non objection
- Non objection expressed by the tutor for participants under tutorship
- Non objection expressed by the participant assisted by their guardian for participants under guardianship
- Non objection expressed by the trusted person (in accordance with art. L1111-6 of Code de la Santé Publique) for participants without the capacity to express non-objection and who are not under legal protection measure
You may not qualify if:
- Expressing opposition to participate in Memento-Plus
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (26)
CHU d'Amiens
Amiens, France
AP-HP - CHU Avicenne
Bobigny, France
CHU de Bordeaux - Pellegrin
Bordeaux, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Hôpitaux Civils de Colmar
Colmar, 68000, France
CHU de Dijon
Dijon, France
CHU de Grenoble
Grenoble, France
CHU de Lille
Lille, France
AP-HM
Marseille, France
CHU de Montpellier
Montpellier, France
CHU de Nancy
Nancy, France
CHU de Nantes
Nantes, France
CHRU de Nice - Institut Claude Pompidou
Nice, France
CHU de Nice - Hôpital de Cimiez
Nice, France
AP-HP - Hôpital BROCA
Paris, France
Ap-Hp La Pitié-Salpêtrière
Paris, France
APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal
Paris, France
CHU de Bordeaux
Pessac, France
CHU de Poitiers
Poitiers, France
CHU de Rouen
Rouen, France
CHU de Saint-Etienne
Saint-Etienne, France
CHU de Strasbourg
Strasbourg, France
CHU de Toulouse - Hôpital Purpan
Toulouse, France
CHU de Toulouse
Toulouse, France
CHU de Tours
Tours, France
Hospice Civil de Lyon
Villeurbanne, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Geneviève CHENE, Prof
CIC-1401 EC - ISPED - CHU de Bodeaux
- STUDY CHAIR
Geneviève CHENE, Prof
CIC-1401 EC - ISPED - CHU de Bodeaux
- STUDY DIRECTOR
Carole DUFOUIL, Director
CIC-1401 EC - ISPED - CHU de Bodeaux
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 27, 2019
First Posted
October 1, 2019
Study Start
December 3, 2019
Primary Completion
December 20, 2024
Study Completion
December 20, 2024
Last Updated
February 17, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share